Yamo Deniz

TL;DR: The anti-inflammatory effects of omalizumab at different sites of allergic inflammation and the clinical benefits of anti-IgE therapy in patients with allergic asthma and allergic rhinitis emphasize the fundamental importance of IgE in allergic inflammation.

TL;DR: Omalizumab pretreatment enhances the safety of RIT for ragweed allergic rhinitis and may be an effective strategy to permit more rapid and higher doses of allergen immunotherapy to be given more safely and with greater efficacy to patients with allergic diseases.

TL;DR: The anti-IgE monoclonal antibody omalizumab is the most recent addition to the list of treatment options for patients with difficult-to-treat asthma and has been shown to reduce exacerbations and emergency visits and improve lung function, symptom scores and quality of life.

TL;DR: Omalizumab reduces the rate of serious asthma exacerbations and the need for unscheduled outpatient visits, emergency room treatment, and hospitalization in patients with moderate-to-severe allergic asthma.

TL;DR: The role of aspirin-exacerbated respiratory disease (AERD) as a risk factor for the development of irreversible airway obstruction was investigated in the TENOR study as discussed by the authors, where subjects with AERD had significantly lower mean postbronchodilator percent predicted FEV 1 compared with subjects with non-aspirin-sensitive asthma.